This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

BRAF V600E and metastatic colorectal cancer

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

BRAF V600E and metastatic colorectal cancer

BRAF is a serine-threonine kinase playing a key role as downstream RAS effector in the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signal transduction cascade

BRAF V600E mutation accounts for 8-10% of metastatic colorectal cancer (mCRC) patients and it is an established prognostic factor (1,2)

  • is recognized as a poor prognostic factor with a median overall survival inferior to 20 months (1)

  • BRAF V600E mutant mCRCs are frequently characterized by hypermethylation, microsatellite instability (MSI) and consensus molecular subtype 1 (CMS1)

  • BRAF mutations account for 8-10% of mCRCs and more than 90% are missense mutations occurring in codon 600, leading to an aminoacidic substitution of a valine for a glutamic acid (V600E)

  • BRAF mutations different from V600E (BRAFnon-V600E) account for about 2% of mCRCs and they have been associated with specific clinicopathological features and a better clinical outcome

  • MSI mCRCs harboring BRAFV600E mutation are always sporadic and do not arise in the context of Lynch Syndrome

  • BRAFV600E mutation is also a target of treatment in various types of malignancies such as melanoma, non-small cell lung cancer (NSCLC), and hairy-cell leukemia
    • BRAF inhibitors in monotherapy do not have the same clinical activity for colorectal cancer relative to other solid tumors harboring an oncogenic BRAF V600E mutation, combination approaches targeting BRAF + MEK +EGFR hold promise for patients BRAF V600E colorectal cancer (3)

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.